The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Welcome back to The UroOnc Minute!

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, sits down with Tyler Seibert, MD, PhD, a radiation oncologist at the University of California, San Diego, to discuss the growing importance of adverse histologic features—particularly cribriform and intraductal carcinoma—in prostate cancer. Although clinicians have long recognized these findings as unfavorable, Seibert explains that recent research suggests their prognostic significance may be greater than previously appreciated, with important implications for risk stratification and treatment selection.

A key focus of the discussion is a reanalysis of the ProtecT trial (NCT02044172), in which investigators conducted a central pathology review using contemporary Gleason grading and assessed biopsy specimens for cribriform and intraductal carcinoma.¹ The analysis found that all metastatic or prostate cancer–specific mortality events occurred in patients with cribriform-positive disease (15-year cumulative incidence, 14%), with risk concentrated among those with pT3b stage and/or grade group 3 or higher disease (15-year cumulative incidence, 27%). Seibert also highlights findings from a modern 3-institution cohort, in which cribriform histology was the strongest predictor of active surveillance failure (HR, 12.7; 95% CI, 4.8 to 33.6; P < .001).² Together, these data suggest that the presence of cribriform or intraductal carcinoma may be an important factor when determining whether patients with intermediate-risk disease are appropriate candidates for active surveillance.

Seibert also discusses the practical importance of ensuring that these histologic features are consistently reported by pathologists. He encourages clinicians to explicitly request documentation of whether cribriform or intraductal carcinoma is present, noting that this information can meaningfully influence clinical decision-making. The conversation also addresses unanswered questions regarding treatment intensification, including whether some patients with cribriform disease may benefit from the addition of androgen deprivation therapy to radiation, as well as how histologic findings should ultimately be integrated with genomic biomarkers and other tools for risk stratification. As research continues to clarify the clinical significance of these features, Seibert and Weiner underscore the need to incorporate detailed pathology into increasingly individualized approaches to prostate cancer management.

REFERENCES